Back to results
US 2024/0299544 A1Published application
Cancer therapies comprising peptide loaded cxcr3- and ccr5-inducing dendritic cells and chemokine modulatory agents
AssigneesHealth Research, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsPawel KALINSKI, Brian CZERNIECKI
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.
Claims31
A method for treating cancer in an individual in need thereof, the cancer comprising at least one tumor, the method comprising administering to the individual:
- a) a combination of autologous dendritic cells i) loaded in vitro with at least one major histocompatibility complex (MHC) Class II- and/or at least one MHC class I-restricted Her2 or Her3 peptide, or ii) exposed in vitro to an intact Her3 protein to process and display Her3 peptides, or a combination or ii) and iii);
- and optionally,
- b) a combination of agents, said combination of agents having a tumor selective chemokine-modulating (CKM) effect.
Dependencies are inferred from the claim text.